share_log

Soligenix Reveals Formation Of European Medical Advisory Board To Provide Additional Medical/Clinical Strategic Guidance; Phase 3 Clinical Study Of HyBryte In CTCL Initiating In 2024

Soligenix Reveals Formation Of European Medical Advisory Board To Provide Additional Medical/Clinical Strategic Guidance; Phase 3 Clinical Study Of HyBryte In CTCL Initiating In 2024

Soligenix公佈成立歐洲醫療顧問委員會,爲提供額外的醫療/臨床戰略指導;HyBryte在CTCL的第三階段臨床研究將於2024年啓動。
Benzinga ·  2024/11/19 20:40

Soligenix Reveals Formation Of European Medical Advisory Board To Provide Additional Medical/Clinical Strategic Guidance; Phase 3 Clinical Study Of HyBryte In CTCL Initiating In 2024

Soligenix公佈成立歐洲醫療顧問委員會,以提供額外的醫療/臨床戰略指導;HyBryte在CTCL的第三階段臨床研究將於2024年啓動。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論